XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.
XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.
DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Daniel T. Scavilla CEO | XMIL Exchange | US24906P1093 ISIN |
| US Country | 14,000 Employees | 9 Jan 2026 Last Dividend | 18 Jul 2006 Last Split | 12 Aug 1987 IPO Date |
DENTSPLY SIRONA Inc., a pioneering company in the dental industry, operates globally to manufacture and distribute a wide array of dental products and technologies. The company's operation is divided into four main segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. Originally known as DENTSPLY International Inc., it underwent a name change to DENTSPLY SIRONA Inc. in February 2016, reflecting the company's expansion and integration of various dental technologies. Founded in 1877 with its headquarters located in Charlotte, North Carolina, DENTSPLY SIRONA serves the professional dental market and the consumable medical device market through third-party distributors, cementing its status as a key player in dental care innovation.